Recent clinical studies have shown that therapy with bimekizumab, a dual IL-17A and IL-17F neutralizing antibody, resulted to pronounced clinical responses in patients with psoriasis (Oliver et al., 2022) and psoriatic arthritis (McInnes et al., 2023). This evidence concerns the gene IL17F and psoriatic arthritis.